Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wake Forest University Health Sciences
Age
30–any
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Normal Healthy Volunteers
Males age 30 years or older.
No prior history of cancer.
Ability to tolerate PET imaging.
Ability to understand and willingness to sign a written informed consent document.
Prostate Cancer Patients:
Patients with histologically confirmed adenocarcinoma of the prostate.
Patients with a clinical staging CT at the time of the first \[F-18\]FMDHT scan.
Patients with at least one single focus of metastatic disease (bone/lymph node or soft tissue) confirmed on other clinical studies, preferably biopsy.
Patients with prior transurethral resection of the prostate are eligible.
Ability to tolerate PET imaging.
Males age 30 years or older.
Ability to understand and willingness to sign a written informed consent document.
Willing to get a PSA evaluated.
You may not be if
Normal Health Volunteers
Prior diagnosis of any cancer (except non-melanoma skin cancer).
Prostate Cancer Patients
Prior diagnosis of cancer except non-melanoma skin cancer.
Prior treatment (other than biopsy) for prostate cancer.
Received radiation therapy, hormonal therapy, surgery or cryotherapy for prostate disease.
Clareo Health | Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT
